专利号:US-8652442-B2 优先权日:2008-11-03 标题 :Bioluminescence imaging of myeloperoxidase activity in vivo, methods, compositions and apparatuses therefor 发明人:PIWNICA-WORMS DAVID; GROSS SHIMON; SHARMA VIJAY; GAMMON SETH 权利人:PIWNICA-WORMS DAVID; GROSS SHIMON; SHARMA VIJAY; GAMMON SETH; UNIV WASHINGTON 摘要:Methods of imaging distribution of myeloperoxidase activity in a subject are disclosed. These methods include the use of bioluminescent substrates, including luminol and wavelength-shifted analogues of luminol. Bioluminescent myeloperoxidase substrates that emit light at longer wavelengths compared to luminol are shown to be useful for imaging myeloperoxidase activity in vivo. The disclosed methods can be used for imaging sites of inflammation and other pathological conditions associated with abnormal levels of MPO activity in vivo. Methods of synthesis of luminol analogues are also disclosed.
专利号:CN-120040355-A 优先权日:2025-02-12 标 题 :A synthesis process and application of luminol monosodium salt precursor for chemiluminescent substrate liquid
1: Schumann S, Kaiser A, Nicoletti F, Mangano K, Fagone P, van Wijk E, Yan Y, Schulz P, Ludescher B, Niedermaier M, von Wegerer J, Rauch P, Setz C, Schubert U, Brysch W. Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19. Int J Mol Sci. 2020 Nov 20;21(22):8803. doi: 10.3390/ijms21228803.
合成参考文献
参考文献:10.1136/bmj.a875 摘要:Tuffs A. Three jailed in Germany for selling a fraudulent cancer cure to terminally ill patients. BMJ. 2008 Jul 18;337():a875. doi: 10.1136/bmj.a875. 参考文献:10.1007/s11696-024-03826-3 摘要:Mozgova O, Blazheyevskiy M, Moroz V, Diadchenko V. Quantitative determination of Na-luminolate by chemiluminescence method in pharmaceutical preparations. Chem. Pap. 2024 Dec 05;79(2):915–22. doi: 10.1007/s11696-024-03826-3. 摘要:Romantsov MG, Sologub TV, Goriacheva LG, Kovalenko SN, Sukhanov DS, Shul'diakov AA, Bondarenko AN, Kovalenko AL, Petrov AIu. [Pathogenetically substantiated therapy of patients with virus hepatitis C, quality of life, and the disease outcome risk (clinical survey)]. Antibiot Khimioter. 2010;55(3-4):45–55.